Abstract:As 3D culture technology advances, new avenues have opened for the development of physiological human cancer models. These preclinical models provide efficient ways to translate basic cancer research into clinical tumor therapies. Recently, cancer organoids have emerged as a model to dissect the more complex tumor microenvironment. Incorporating cancer organoids into preclinical programs have the potential to increase the success rate of oncology drug development and recapitulate the most efficacious treatment regimens for cancer patients. In this review, four main types of cancer organoids are introduced, their applications, advantages, limitations, and prospects are discussed, as well as the recent application of single-cell RNA-sequencing (scRNA-seq) in exploring cancer organoids to advance this field. The 3D cancer organoid, a model to dissect the complex tumor microenvironment, enables ex vivo analysis of in vivo tumors accurately. Currently, four main types of cancer organoids are classified with their advantages and disadvantages. The incorporation of cancer organoids into preclinical programs could increase the success rate of oncology drug development and treatment regimens for cancer patients. image

Organoids for Cancer Research: Advances and Challenges